- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01134939
Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data
Non-interventional Observational Study With Viramune® Plus Antiretroviral Backbone Combination in HIV-infected Women and Male Patients. Gender Specific Evaluation of Data.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Time Perspective:
retro- and prospective
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Aachen, Tyskland
- Boehringer Ingelheim Investigational Site 23
-
Berlin, Tyskland
- Boehringer Ingelheim Investigational Site 10
-
Berlin, Tyskland
- Boehringer Ingelheim Investigational Site 11
-
Berlin, Tyskland
- Boehringer Ingelheim Investigational Site 14
-
Berlin, Tyskland
- Boehringer Ingelheim Investigational Site 19
-
Berlin, Tyskland
- Boehringer Ingelheim Investigational Site 26
-
Berlin, Tyskland
- Boehringer Ingelheim Investigational Site 28
-
Berlin, Tyskland
- Boehringer Ingelheim Investigational Site 33
-
Berlin, Tyskland
- Boehringer Ingelheim Investigational Site 4
-
Berlin, Tyskland
- Boehringer Ingelheim Investigational Site 5
-
Berlin, Tyskland
- Boehringer Ingelheim Investigational Site 8
-
Berlin, Tyskland
- Boehringer Ingelheim Investigational Site 9
-
Chemnitz, Tyskland
- Boehringer Ingelheim Investigational Site 31
-
Dortmund, Tyskland
- Boehringer Ingelheim Investigational Site 29
-
Düsseldorf, Tyskland
- Boehringer Ingelheim Investigational Site 27
-
Frankfurt, Tyskland
- Boehringer Ingelheim Investigational Site 17
-
Frankfurt, Tyskland
- Boehringer Ingelheim Investigational Site 1
-
Freiburg, Tyskland
- Boehringer Ingelheim Investigational Site 2
-
Giessen, Tyskland
- Boehringer Ingelheim Investigational Site 34
-
Hamburg, Tyskland
- Boehringer Ingelheim Investigational Site 22
-
Hamburg, Tyskland
- Boehringer Ingelheim Investigational Site 6
-
Hannover, Tyskland
- Boehringer Ingelheim Investigational Site 12
-
Hannover, Tyskland
- Boehringer Ingelheim Investigational Site 16
-
Karlsruhe, Tyskland
- Boehringer Ingelheim Investigational Site 32
-
Koblenz, Tyskland
- Boehringer Ingelheim Investigational Site 15
-
Köln, Tyskland
- Boehringer Ingelheim Investigational Site 25
-
Leipzig, Tyskland
- Boehringer Ingelheim Investigational Site 21
-
München, Tyskland
- Boehringer Ingelheim Investigational Site 20
-
München, Tyskland
- Boehringer Ingelheim Investigational Site 24
-
München, Tyskland
- Boehringer Ingelheim Investigational Site 3
-
München, Tyskland
- Boehringer Ingelheim Investigational Site 7
-
Münster, Tyskland
- Boehringer Ingelheim Investigational Site 13
-
Osnabrück, Tyskland
- Boehringer Ingelheim Investigational Site 18
-
Stuttgart, Tyskland
- Boehringer Ingelheim Investigational Site 30
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion criteria:
The inclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC
Exclusion criteria:
The inclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
Kohorter og intervensjoner
Gruppe / Kohort |
---|
HIV-infected women and men
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Patients With Virologic Response (VR) After 36 Months
Tidsramme: 36 months
|
VR is defined as HIV viral load of < 50 copies/mL before month 36 and without subsequent rebound or change of ARV therapy. A rebound is defined by two consecutive measurements of VL ≥ 50 copies/ml, at least two weeks apart. A change of ARV therapy is defined as a permanent discontinuation of Viramune®. A change in the background therapy due to toxicity or intolerance is not considered failure for the analysis. Therefore, a patient remains a treatment responder in this case if all other criteria are fulfilled. A rebound is defined by two consecutive measurements of VL ≥ 50 copies/ml, at least two weeks apart, after two consecutive measurements of VL< 50 copies/ml. |
36 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Changes in the Viral Load After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The change in the log10 viral load from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months.
Therefore, a negative change represents a decrease in viral load.
|
Baseline and 36 months
|
Changes in the CD4+ Cell Count After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The change in the Cluster of differentiation 4 (CD4+) cell count from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase in CD4+ cell count.
|
Baseline and 36 months
|
Changes in the Laboratory Data (Total Cholesterol) After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The changes in the laboratory data (Total Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (HDL Cholesterol) After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (LDL Cholesterol) After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The changes in the laboratory data (Low density protein (LDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (Triglycerides) After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The changes in the laboratory data (Triglycerides) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (Blood Glucose) After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The changes in the laboratory data (Blood Glucose) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data ( ALT) After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (AST) After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (Gamma-GT) After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (Creatinine) After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The changes in the laboratory data (Creatinine) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Changes in the Laboratory Data (Haemoglobin) After 36 Months From Baseline
Tidsramme: Baseline and 36 months
|
The changes in the laboratory data (Haemoglobin) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months.
Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .
|
Baseline and 36 months
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 1100.1536
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på HIV-infeksjoner
-
Universidad del DesarrolloFullførtHealthcare Associated InfectionChile
-
Imelda Hospital, BonheidenFullførtHealthcare Associated InfectionBelgia
-
Centre Hospitalier Universitaire de NīmesRekrutteringEldre | Healthcare Associated InfectionFrankrike
-
Centre Hospitalier Universitaire, AmiensFullførtHealthcare Associated Infection | IglerFrankrike
-
Johns Hopkins UniversityFullførtHealthcare Associated Infection | Multiresistente organismer
-
University of PennsylvaniaFullførtAntimikrobiell resistensForente stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentFullførtMenneskelig mikrobiomForente stater
-
Universidad Autonoma de Nuevo LeonUkjentHelsetilknyttede infeksjoner
-
Children's Hospital Medical Center, CincinnatiAvsluttetAllogen hematopoetisk celletransplantasjonForente stater
-
Central Hospital, Nancy, FranceHar ikke rekruttert ennåHealthcare Associated Infection | Antibiotika